JNJ-75276617

Generic Name: JNJ-75276617

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1

Withdrawn

Conditions: Acute Leukemias
Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: JNJ-75276617
Drug: Fludarabine
Drug: Cytarabine
Drug: Intrathecal Chemotherapy
Drug: Dexamethasone
Drug: Vincristine
Drug: Pegaspargase

First Posted Date: 2022-08-30

Last Posted Date: 2024-08-22

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05521087

Locations: 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 8 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy